Esperion Therapeutics (ESPR) to Release Quarterly Earnings on Thursday

Esperion Therapeutics (NASDAQ:ESPR) is set to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million. On average, analysts expect Esperion Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $2.13 on Thursday. Esperion Therapeutics has a 1-year low of $0.79 and a 1-year high of $3.40. The business has a 50 day simple moving average of $1.86 and a two-hundred day simple moving average of $2.12. The stock has a market capitalization of $403.55 million, a PE ratio of -2.15 and a beta of 1.00.

Wall Street Analyst Weigh In

ESPR has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. Needham & Company LLC reduced their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. Finally, StockNews.com raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, October 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Hold” and an average price target of $8.17.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.